China’s first original target gene therapy for hemophilia B was born in Tianfu International Biocity

2022-04-30 0 By

Yesterday, journalists noticed that the official website of the Ministry of Science and Technology updated the approval results of the second batch of administrative licensing of Human genetic resources in China in 2022.Among them, the clinical study of “Evaluating the safety and effectiveness of ZS801 adeno-associated virus vector expressing human coagulation factor IX gene therapy technology in hemophilia B patients”, AAV (adeno-associated virus) gene therapy clinical study was reviewed by China Human Genetic Resources Management Office.It is reported that the project is jointly initiated by Sichuan Zhishanweixin Biotechnology Co., LTD., an enterprise located in Chengdu Tianfu International Biological City, and will be carried out clinical research in hematology Hospital of Chinese Academy of Medical Sciences.This marks that China’s first original target gene therapy for hemophilia B was born in Chengdu Tianfu International Biocity, and chengdu’s biomedical industry has achieved an important milestone in the field of gene therapy.The reporter learned that ZS801 project will be used for the treatment of hemophilia B, compared with the traditional enzyme replacement therapy, is expected to achieve a “needle cure”;Compared with competing products, ZS801 uses the original drug target independently developed by zhishanweixin biological united well-known domestic medical institutions, the efficacy is comparable to foreign varieties, and has independent intellectual property rights.Led by Dr. Dong Biao, professor of the State Key Laboratory of Biotherapy at West China Hospital of Sichuan University, Zhishanweixin is committed to developing affordable AAV gene drugs for Chinese people.(reporter Wu Yifei) statement: reprint this article is for the purpose of passing more information.If the source is wrong or violated your legitimate rights and interests, please contact the author with proof of ownership, we will promptly correct, delete, thank you.Email address: